Latest MD Biosciences Stories

The porcine sciatica model can evaluate efficacy and PK/PD from the same subject and may provide more clinically relevant data at preclinical stages minimizing expensive failures. St Paul, MN (PRWEB) October 03, 2012 MD Biosciences has developed a large preclinical model of neuropathic pain for preclinical evaluation of analgesic or neuroprotective therapies. The sciatica model was developed in the pig, as the innervation is similar to that of humans, providing more clinically relevant...

ST PAUL, Minn., May 2, 2012 /PRNewswire-iReach/ -- The most common models for evaluating skin-related inflammation are time consuming and expensive. While they provide valuable data, they don't allow for rapid and cost effective evaluation of therapeutics earlier in the preclinical pipeline. In response to this need for more convenient and cost effective models, researchers (Van der Fits et al, 2009) developed a model using Imiquimod (IMQ) to induce psoriasis-like inflammation....

MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its pre-clinical capabilities at the 2008 Neuroscience Conference in Washington, DC, November 15 - 19th, 2008, booth 1825. Capabilities included in the showcase are efficacy disease models within Multiple Sclerosis (MS), Gliosis, Parkinson's Disease, Nociceptive, Neuropathic and Inflammatory Pain. Multiple Sclerosis: Multiple sclerosis is a demyelinating disease of the CNS. Due...

MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its inflammations related pre-clinical services and research products at the 15th International Inflammation Research Association (IRA) Conference, September 21-24, Chantilly, VA. Capabilities featured will be pre-clinical efficacy disease models and research products for drug discovery and research. MD Biosciences will be hosting a lunch and learn session titled "Discovery of novel...